On January 17, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk for adult patients with unresectable or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
For more information, read the FDA announcement and the AstraZeneca press release.
Posted 1/28/2025
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
